CBD, Nutrient Metabolism and Energy Intake

February 4, 2025 updated by: Lewis James, Loughborough University

Effects of Acute Cannabidiol (CBD) Supplementation on Nutrient Metabolism and Energy Intake in Healthy Adults

CBD may affect metabolic control and energy intake. However, there is currently little data regarding these specific outcomes in humans. Therefore, this study will investigate whether a single 300 mg dose of CBD can improve metabolic control following a meal and/or reduce energy intake at a subsequent meal. Healthy, adult volunteers will complete two conditions in a crossover design, comparing outcomes following both CBD and placebo supplementation.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • Leicestershire
      • Loughborough, Leicestershire, United Kingdom, LE11 3TU
        • Loughborough University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

• Self-report as healthy, male or female, aged 18-50, body mass index ≥18.5 and <30.0

Exclusion Criteria:

  • Currently engage in >10 hours moderate or vigorous intensity physical activity per week
  • Have consumed CBD or cannabis at all within the past two months
  • Have used CBD or cannabis regularly (>2x in a week) within the past four months
  • Are suffering from any clinically significant illness
  • Have regularly used tobacco within the previous 6 months (> 2/week)
  • Currently use any prescription or over-the-counter medications (except for hormonal contraception and simple painkillers)
  • Have given a standard blood donation within 30 days of screening
  • Are currently pregnant or lactating
  • Are allergic/intolerant to any ingredients in food items provided during the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cannabidiol
300 mg CBD (KannaSwiss, Kölliken, Switzerland) dissolved in 1 ml hemp oil. Provided orally in gelatin capsules.
Dietary supplement: Acute oral CBD supplementation
1 ml hemp oil containing 300 mg CBD, within gelatin capsules, ingested orally.
Placebo Comparator: Placebo
1 ml hemp oil. Provided orally in gelatin capsules.
Dietary supplement: Acute oral placebo supplementation
1 ml hemp oil containing no CBD, within gelatin capsules, ingested orally.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Energy intake
Time Frame: ~5-30 minutes (time taken to eat a single meal)
Self-selected energy intake at an ad libitum mixed meal
~5-30 minutes (time taken to eat a single meal)
Postprandial Glycaemia
Time Frame: 3 hours
Plasma glucose response to a mixed meal (plasma glucose concentrations and area under curve)
3 hours
Postprandial Triglyceridaemia
Time Frame: 3 hours
Plasma triglyceride response to a mixed meal (plasma triglyceride concentrations and area under curve)
3 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postprandial Insulinaemia
Time Frame: 3 hours
Plasma Insulin response to a mixed meal (plasma insulin concentrations and area under curve)
3 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Loughborough University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 30, 2021

Primary Completion (Actual)

April 30, 2022

Study Completion (Actual)

April 30, 2022

Study Registration Dates

First Submitted

February 23, 2022

First Submitted That Met QC Criteria

November 9, 2022

First Posted (Actual)

November 16, 2022

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 4, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 5553 (Other Identifier: COMITATO ETICO TERRITORIALE LOMBARDIA 3)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe